Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors

被引:69
作者
Crippa, Stefano [1 ,3 ]
Partelli, Stefano [1 ,3 ]
Zamboni, Giuseppe [2 ,4 ]
Scarpa, Aldo [2 ]
Tamburrino, Domenico [1 ]
Bassi, Claudio [1 ]
Pederzoli, Paolo [1 ]
Falconi, Massimo [1 ]
机构
[1] Univ Verona, Policlin GB Rossi, Dept Surg, I-37100 Verona, Italy
[2] Univ Verona, Policlin GB Rossi, Dept Pathol, I-37100 Verona, Italy
[3] Osped Sacro Cuore Don Calabria, Dept Surg, Negrar, VR, Italy
[4] Osped Sacro Cuore Don Calabria, Dept Pathol, Negrar, VR, Italy
关键词
NEUROENDOCRINE TUMORS; SHORT-TERM; MANAGEMENT; NEOPLASMS; EXPERIENCE; RESECTIONS; SYSTEM;
D O I
10.1016/j.surg.2013.08.002
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Incidentally discovered nonfunctioning pancreatic endocrine tumors (NF-pNETs) increasingly are being detected, and their management is debated. Moreover, the prognostic importance of incidental diagnosis for locally advanced or metastatic NF-pNETs is unknown. The aim of this study is. to analyze the outcomes of incidentally discovered/symptomatic NF-pNETs stratified by tumor stage. A preliminary experience with nonoperative treatment of incidental NF-pNETs is reported. Methods. Consecutive patients with symptomatic/incidental NF-PETs observed between, 1990 and 2009 were analyzed, with different tumor stages considered. Nonoperative management of incidental NF-pNETs was evaluated. Results. Among 355 patients with NF-pNETs, the diagnosis was incidental in 124 (35%). Incidental NF-pNETs were associated more commonly with lower tumor stages compared with symptomatic tumors (P < .0001), but 30% of incidental NF-pNETs were stage III-IV Incidental NF-pNETs had greater rates of radical resections and of R0 margins (P < .0001). Five-year progression-free survival (PFS) was 83% and 32%. for incidental and symptomatic NF-pNETs, respectively (P < .0001). Five-year PFS was better for incidental NF-pNETs compared with symptomatic tumors for each tumor stage, including stage III (69% vs 27%, P < .0001) and stage IV (60% vs 17%, P = .112). After a median follow-up of 36 months, there was no tumor progression in 12 patients who underwent nonoperative management of incidental NF-pNETs. Conclusion. A total of 30% of incidental NF-pNETs present with stage disease. PFS is much greater for incidental NF-pNETs compared with symptomatic patients, and this difference is evident also for stage III-IV tumors, suggesting that absence of symptoms may indicate a less-aggressive disease. Nonoperative management can be an alternative to surgery in selected incidental NF-pNETs.
引用
收藏
页码:145 / 153
页数:9
相关论文
共 26 条
  • [11] ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors
    Falconi, Massimo
    Bartsch, Detlef Klaus
    Eriksson, Barbro
    Kloeppel, Guenter
    Lopes, Jose M.
    O'Connor, Juan M.
    Salazar, Ramon
    Taal, Babs G.
    Vullierme, Marie Pierre
    O'Toole, Dermot
    [J]. NEUROENDOCRINOLOGY, 2012, 95 (02) : 120 - 134
  • [12] Surgical management of pancreatic endocrine tumors
    Fendrich, Volker
    Waldmann, Jens
    Bartsch, Detlef K.
    Langer, Peter
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (07) : 419 - 428
  • [13] Differences in survival by histologic type of pancreatic cancer
    Fesinmeyer, MD
    Austin, MA
    Li, CI
    De Roos, AJ
    Bowen, DJ
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (07) : 1766 - 1773
  • [14] Trends in Hospital Volume and Operative Mortality for High-Risk Surgery
    Finks, Jonathan F.
    Osborne, Nicholas H.
    Birkmeyer, John D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (22) : 2128 - 2137
  • [15] Implications of Incidentally Discovered, Nonfunctioning Pancreatic Endocrine Tumors Short-term and Long-term Patient Outcomes
    Haynes, Alex B.
    Deshpande, Vikram
    Ingkakul, Thun
    Vagefi, Parsia A.
    Szymonifka, Jackie
    Thayer, Sarah P.
    Ferrone, Cristina R.
    Wargo, Jennifer A.
    Warshaw, Andrew L.
    Fernandez-del Castillo, Carlos
    [J]. ARCHIVES OF SURGERY, 2011, 146 (05) : 534 - 538
  • [16] Pancreatic Neuroendocrine Tumors
    Hill, Joshua S.
    McPhee, James T.
    McDade, Theodore P.
    Zhou, Zheng
    Sullivan, Mary E.
    Whalen, Giles F.
    Tseng, Jennifer F.
    [J]. CANCER, 2009, 115 (04) : 741 - 751
  • [17] The gastroenteropancreatic neuroendocrine cell system and its tumors
    Klöppel, G
    Perren, A
    Heitz, PU
    [J]. GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR DISEASE: MOLECULAR AND CELL BIOLOGICAL ASPECTS, 2004, 1014 : 13 - 27
  • [18] Serotonin-Producing Enterochromaffin Cell Tumors of the Pancreas Clinicopathologic Study of 15 Cases and Comparison With Intestinal Enterochromaffin Cell Tumors
    La Rosa, Stefano
    Franzi, Francesca
    Albarello, Luca
    Schmitt, Anja
    Bernasconi, Barbara
    Tibiletti, Maria Grazia
    Finzi, Giovanna
    Placidi, Claudia
    Perren, Aurel
    Capella, Carlo
    [J]. PANCREAS, 2011, 40 (06) : 883 - 895
  • [19] Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): Role for nonoperative management
    Lee, Louis C.
    Grant, Clive S.
    Salomao, Diva R.
    Fletcher, Joel G.
    Takahashi, Naoki
    Fidler, Jeff L.
    Levy, Michael J.
    Huebner, Marianne
    [J]. SURGERY, 2012, 152 (06) : 965 - 973
  • [20] Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors
    Modlin, Irvin M.
    Moss, Steven F.
    Chung, Daniel C.
    Jensen, Robert T.
    Snyderwine, Elizabeth
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (18): : 1282 - 1289